Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling malignant pleural effusion recurrence in EGFR-mutated lung cancer patients

BACKGROUND: Epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) patients benefit from EGFR-tyrosine kinase inhibitors (TKIs) therapy. There are few studies comparing the efficacy between intrapleural chemotherapy combination with TKIs and TKIs alone in controlling re-a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Thorac Dis
Autores principales: Wang, Wenxian, Jiang, Xiaowen, Zhang, Yiping, Song, Yong, Song, Zhengbo
Formato: Artigo
Lenguaje:Inglês
Publicado: AME Publishing Company 2019
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6790470/
https://ncbi.nlm.nih.gov/pubmed/31656643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2019.09.36
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares